Table 2.

Results for patients with Parkinson disease in oral cannabidiol (CBD) and placebo treatment groups.

			Pretreatment		Posttreatment		P value
Presence of seborrheic dermatitis a , n (%; 95% CI)
	CBD	12 (46.2; 30.5-69.9)		9 (34.6; 20.4-58.7)		.26
	Placebo	15 (55.6; 39.7-77.9)		18 (66.7; 51.1-87.0)		.26
	Treatment effect	N/Ab		N/A		.12
SEDASI c average d , mean (95% CI; SD)
	CBD	3.63 (1.41-5.86; 5.50)		3.79 (1.38-6.20; 5.96)		.81
	Placebo	5.39 (2.75-8.03; 6.68)		4.65 (2.76-6.54; 4.77)		.35
	Treatment effect	N/A		N/A		.38

^aPresence of seborrheic dermatitis indicates patients exhibiting any signs of seborrheic dermatitis after assessing the final SEDASI score. Numbers calculated for generalized estimating equation model with log link (ie, relative risk model with repeated measures).

^bN/A: not applicable.

^cSEDASI: Seborrheic Dermatitis Area and Severity Index.

^dSEDASI average is calculated by averaging the two scores assigned by independent reviewers to each patient.